BRAF and colorectal carcinoma: We therefore postulate the idea that novel strategies aimed at improving the efficacy of ICI in BRAF-mutated CRC patients should combine the use of anti-PD(L)1 antibodies with inhibitors of other receptors involved in the regulation of immune responses that could help to revert this immunosuppressive phenotype.